Evidence map›Paper›PMID 42656575›Full record

ReviewFrontiers in aging neuroscience2026

The delta-opioid receptor: a therapeutic target for Alzheimer's disease.

Yuan Xu, Wei Guan, Yilin Yang, Yujiao Yang, Ying Xia, Ya Peng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuan XuDepartments of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Wei GuanDepartments of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Yilin YangDepartments of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Yujiao YangDepartment of Geriatrics, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Ying XiaShanghai Key Laboratory of Acupuncture Mechanism and Acupoint Function, Fudan University, Shanghai, China.
Ya PengDepartments of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) presents a complex pathogenesis involving amyloid-β (Aβ) plaques, tau tangles, and neuroinflammation. Recent evidence highlights δ-opioid receptor (DOR) as a unique and promising therapeutic target for AD. This review summarizes current knowledge on DOR's multifaceted neuroprotective role in AD pathology. While its involvement in Aβ regulation appears context-dependent, DOR activation consistently attenuates tau hyperphosphorylation, modulates microglial dysfunction, suppresses harmful neuroinflammation and inhibits complement-mediated synaptic pruning. All these findings have been well documented in

Indexed as

Alzheimer's diseaseamyloid-β plaquesmicroglianeuroinflammationtau tanglesδ-opioid receptor

Identifiers

PMID42656575
PMCPMC13506806

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.